GSK Links with French Venture Firm to Target Rare Diseases
GlaxoSmithKline is investing 17.5 million euros ($23.5 million) in a new venture fund to invest in drugs for rare diseases, underscoring the growing role of big drugmakers in backing start-up companies, Reuters reported.
20 June 2013•1 min read
